Financial Toxicity and Equitable Access to Clinical Trials

Financial Toxicity and Equitable Access to Clinical Trials

Annual-Meeting

7 months
65 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Yousuf Zafar, MD, discuses the role of Real World Evidence in cancer care.
Financial barriers to clinical trial enrollment are an area of active investigation. Financial toxicity as a concept describes how high costs and financial burden can lead to compromised care and outcomes. Despite the potential to yield large survival benefits and improved access to cutting-edge therapies, less than 5% of adult patients with cancer are enrolled in a clinical trial. Disparities in trial enrollment exist along age, ethnic, and sociodemographic lines, with younger, poorer, nonwhite patients with private insurancethe exact population who may be at highest risk for financial toxicityless likely to participate. Cost and insurance concerns remain an obstacle for clinical trial enrollment for certain patient populations. Changing the clinical trial paradigm with a focus on addressing structural and clinical barriers to clinical trial enrollment is paramount. This includes expanding access to clinical trials within community populations, advocating for health policy changes to guarantee insurance coverage of clinical trial standard-of-care health care, and considering noncoercive financial assistance (particularly for indirect costs like travel and lodging) for participants to defray their additional costs of participation. Additional steps toward education, cost transparency, and expansion of foundation assistance may also improve equitable access to clinical trials for all.

Up Next Autoplay
Phase 3 TAGS Study Evaluating LONSURF
Phase 3 TAGS Study Evaluating LONSURF
Category: Gastrointestinal Cancer
21 Views
Cancer-News 4 weeks
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Category: Gastrointestinal Cancer
15 Views
Massachusetts General Hospital 3 months
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Category: Gastrointestinal Cancer
27 Views
Massachusetts General Hospital 3 months
Intestinal Tumor Commonly Asked Questions
Intestinal Tumor Commonly Asked Questions
Category: Gastrointestinal Cancer
24 Views
Massachusetts General Hospital 3 months
Drug Resistance Found As Intestinal Tumor
Drug Resistance Found As Intestinal Tumor
Category: Gastrointestinal Cancer
25 Views
Massachusetts General Hospital 3 months
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1  Positive Advanced Gastric Cancer
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
Category: Gastrointestinal Cancer
182 Views
obr 7 months
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
Category: Gastrointestinal Cancer
219 Views
Annual-Meeting 7 months
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Category: Gastrointestinal Cancer
27 Views
Annual-Meeting 7 months
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Category: Gastrointestinal Cancer
127 Views
Annual-Meeting 7 months
Caring For Every Patient And Learning From Every Patient
Caring For Every Patient And Learning From Every Patient
Category: Gastrointestinal Cancer
160 Views
Annual-Meeting 7 months